Skandinaviska Enskilda Banken AB publ increased its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 24.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 216,600 shares of the company’s stock after buying an additional 42,400 shares during the period. Skandinaviska Enskilda Banken AB publ owned approximately 0.47% of Amphastar Pharmaceuticals worth $3,141,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in AMPH. Vanguard Group Inc. boosted its position in Amphastar Pharmaceuticals by 0.4% in the first quarter. Vanguard Group Inc. now owns 2,179,764 shares of the company’s stock worth $31,607,000 after buying an additional 8,744 shares in the last quarter. State Street Corp raised its stake in Amphastar Pharmaceuticals by 11.1% in the first quarter. State Street Corp now owns 1,062,439 shares of the company’s stock valued at $15,406,000 after buying an additional 106,448 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Amphastar Pharmaceuticals by 32.5% in the first quarter. Dimensional Fund Advisors LP now owns 1,061,188 shares of the company’s stock valued at $15,388,000 after buying an additional 260,288 shares during the last quarter. Rothschild Asset Management Inc. acquired a new stake in Amphastar Pharmaceuticals during the first quarter valued at about $9,056,000. Finally, Teachers Advisors LLC raised its stake in Amphastar Pharmaceuticals by 0.3% in the fourth quarter. Teachers Advisors LLC now owns 542,953 shares of the company’s stock valued at $10,001,000 after buying an additional 1,693 shares during the last quarter. 45.32% of the stock is currently owned by hedge funds and other institutional investors.
Amphastar Pharmaceuticals, Inc. (NASDAQ AMPH) opened at 17.95 on Tuesday. The stock’s 50 day moving average is $16.62 and its 200 day moving average is $16.18. Amphastar Pharmaceuticals, Inc. has a 52 week low of $12.05 and a 52 week high of $21.75. The stock has a market cap of $820.98 million, a PE ratio of 94.47 and a beta of 1.68.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Monday, May 8th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by $0.03. The firm had revenue of $56.67 million during the quarter, compared to analyst estimates of $63.74 million. Amphastar Pharmaceuticals had a net margin of 3.54% and a return on equity of 2.69%. The business’s quarterly revenue was down 4.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.12 earnings per share. Analysts predict that Amphastar Pharmaceuticals, Inc. will post $0.40 EPS for the current year.
WARNING: This piece was originally published by Stock Observer and is owned by of Stock Observer. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://www.thestockobserver.com/2017/07/18/skandinaviska-enskilda-banken-ab-publ-boosts-stake-in-amphastar-pharmaceuticals-inc-amph-updated-updated.html.
Several analysts have issued reports on AMPH shares. TheStreet upgraded shares of Amphastar Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Monday, June 26th. Jefferies Group LLC decreased their target price on shares of Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, May 10th. Finally, Zacks Investment Research downgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, May 16th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. Amphastar Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $20.14.
In other news, Director Richard K. Prins sold 7,500 shares of the company’s stock in a transaction on Thursday, May 11th. The shares were sold at an average price of $15.43, for a total transaction of $115,725.00. Following the transaction, the director now directly owns 30,500 shares of the company’s stock, valued at approximately $470,615. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Michael A. Zasloff sold 15,000 shares of the company’s stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $17.01, for a total transaction of $255,150.00. Following the transaction, the director now directly owns 47,411 shares in the company, valued at $806,461.11. The disclosure for this sale can be found here. Insiders sold a total of 43,982 shares of company stock worth $735,850 over the last three months. 11.10% of the stock is currently owned by corporate insiders.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.